Patents by Inventor Janus Schreiber Larsen

Janus Schreiber Larsen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • DIFLUOROMETHYL-PYRIDIN-2-YL TRIAZOLES
    Publication number: 20230286946
    Abstract: The present invention relates to difluoromethyl-pyridin-2-yl triazoles of general formula (I) which are modulators of GABAA receptors containing the ?5 subunit, useful in treating central nervous system diseases and other diseases. In addition, the invention relates to processes for preparing pharmaceutical compositions as well as processes for the manufacture of compounds according to the invention.
    Type: Application
    Filed: August 4, 2021
    Publication date: September 14, 2023
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Florian Montel, Yunhai Cui, Niklas Heine, Oliver Hucke, Radoslaw Lipinski, Stefan Peters, Janus Schreiber Larsen
  • POTASSIUM CHANNEL MODULATORS
    Publication number: 20210380571
    Abstract: Provided are compounds and pharmaceutically acceptable salts thereof, which are useful for treating a variety of diseases, disorders or conditions, associated with potassium channels.
    Type: Application
    Filed: January 15, 2021
    Publication date: December 9, 2021
    Inventors: Dipak Vasantrao Amrutkar, Kelly Foster, Thomas Amos Jacobsen, Martin R. Jefson, Gregg F. Keaney, Janus Schreiber Larsen, Karin Sandager Nielsen
  • DIFLUOROMETHYL-PHENYL TRIAZOLES
    Publication number: 20210147393
    Abstract: The present invention relates to difluoromethyl-phenyl triazoles of general formula (1) which are modulators of GABAA receptors containing the ?5 subunit, useful in treating central nervous system diseases and other diseases. In addition, the invention relates to processes for preparing pharmaceutical compositions as well as processes for manufacture the compounds according to the invention.
    Type: Application
    Filed: January 27, 2021
    Publication date: May 20, 2021
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Janus Schreiber Larsen, Florian Binder, Yunhai Cui, Oliver Hucke, Radoslaw Lipinski, Florian Montel, Markus Ostermeier, Alexandre Perera, Stefan Peters
  • Difluoromethyl-phenyl triazoles
    Patent number: 10941137
    Abstract: The present invention relates to difluoromethyl-phenyl triazoles of general formula (I) which are modulators of GABAA receptors containing the ?5 subunit, useful in treating central nervous system diseases and other diseases. In addition, the invention relates to processes for preparing pharmaceutical compositions as well as processes for manufacture the compounds according to the invention.
    Type: Grant
    Filed: July 19, 2019
    Date of Patent: March 9, 2021
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Janus Schreiber Larsen, Florian Binder, Yunhai Cui, Oliver Hucke, Radoslaw Lipinski, Florian Montel, Markus Ostermeier, Alexandre Perera, Stefan Peters
  • Potassium channel modulators
    Patent number: 10774064
    Abstract: Provided are novel compounds of Formula (I): and pharmaceutically acceptable salts thereof, which are useful for treating a variety of diseases, disorders or conditions which can be affected by potassium channel modulation. Also provided are pharmaceutical compositions comprising the novel compounds of Formula (I), pharmaceutically acceptable salts thereof, and methods for their use in treating one or more diseases, disorders or conditions, associated with potassium channels.
    Type: Grant
    Filed: June 2, 2017
    Date of Patent: September 15, 2020
    Assignee: Cadent Therapeutics, Inc.
    Inventors: Birgitte Langer Eriksen, Magnus Gustafsson, Charlotte Hougaard, Thomas Amos Jacobsen, Martin R. Jefson, Gregg F. Keaney, Jessica Klein, Janus Schreiber Larsen, John A. Lowe, III, John M. McCall, Dorte Strøbæk, Nadia Lybøl von Schoubye
  • Potassium channel modulators
    Patent number: 10717728
    Abstract: Provided are compounds of the formula: and pharmaceutically acceptable salts and compositions thereof, which are useful for treating a variety of diseases, disorders or conditions, associated with potassium channels.
    Type: Grant
    Filed: June 4, 2019
    Date of Patent: July 21, 2020
    Assignee: Cadent Therapeutics, Inc.
    Inventors: Dipak Vasantrao Amrutkar, Kelly Foster, Thomas Amos Jacobsen, Martin R. Jefson, Gregg F. Keaney, Janus Schreiber Larsen, Karin Sandager Nielsen
  • DIFLUOROMETHYL-PHENYL TRIAZOLES
    Publication number: 20200024261
    Abstract: The present invention relates to difluoromethyl-phenyl triazoles of general formula (I) which are modulators of GABAA receptors containing the ?5 subunit, useful in treating central nervous system diseases and other diseases. In addition, the invention relates to processes for preparing pharmaceutical compositions as well as processes for manufacture the compounds according to the invention.
    Type: Application
    Filed: July 19, 2019
    Publication date: January 23, 2020
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Janus Schreiber Larsen, Florian Binder, Yunhai Cui, Oliver Hucke, Radoslaw Lipinski, Florian Montel, Markus Ostermeier, Alexandre Perera, Stefan Peters
  • POTASSIUM CHANNEL MODULATORS
    Publication number: 20190352293
    Abstract: Provided are compounds and pharmaceutically acceptable salts thereof, which are useful for treating a variety of diseases, disorders or conditions, associated with potassium channels.
    Type: Application
    Filed: June 4, 2019
    Publication date: November 21, 2019
    Inventors: Dipak Vasantrao Amrutkar, Kelly Foster, Thomas Amos Jacobsen, Martin R. Jefson, Gregg F. Keaney, Janus Schreiber Larsen, Karin Sandager Nielsen
  • POTASSIUM CHANNEL MODULATORS
    Publication number: 20190218200
    Abstract: Provided are novel compounds of Formula (I): and pharmaceutically acceptable salts thereof, which are useful for treating a variety of diseases, disorders or conditions which can be affected by potassium channel modulation. Also provided are pharmaceutical compositions comprising the novel compounds of Formula (I), pharmaceutically acceptable salts thereof, and methods for their use in treating one or more diseases, disorders or conditions, associated with potassium channels.
    Type: Application
    Filed: June 2, 2017
    Publication date: July 18, 2019
    Inventors: Birgitte Langer Eriksen, Magnus Gustafsson, Charlotte Hougaard, Thomas Amos Jacobsen, Martin R. Jefson, Gregg F. Keaney, Jessica Klein, Janus Schreiber Larsen, John A. Lowe, III, John M. McCall, Dorte Strøbæk, Nadia Lybøl von Schoubye
  • Potassium channel modulators
    Patent number: 10351553
    Abstract: Provided herein are compounds of the formula: or pharmaceutically acceptable salts thereof, and compositions comprising such compounds for use in the treatment of diseases or conditions responsive to modulation of the small conductance calcium-activated potassium channel (SK channel).
    Type: Grant
    Filed: March 28, 2018
    Date of Patent: July 16, 2019
    Assignee: Cadent Therapeutics, Inc.
    Inventors: Dipak Vasantrao Amrutkar, Kelly Foster, Thomas Amos Jacobsen, Martin R. Jefson, Gregg F. Keaney, Janus Schreiber Larsen, Karin Sandager Nielsen
  • POTASSIUM CHANNEL MODULATORS
    Publication number: 20180215746
    Abstract: Provided are compounds and pharmaceutically acceptable salts thereof, which are useful for treating a variety of diseases, disorders or conditions, associated with potassium channels.
    Type: Application
    Filed: March 28, 2018
    Publication date: August 2, 2018
    Inventors: Dipak Vasantrao Amrutkar, Kelly Foster, Thomas Amos Jacobsen, Martin R. Jefson, Gregg F. Keaney, Janus Schreiber Larsen, Karin Sandager Nielsen
  • Potassium channel modulators
    Patent number: 9975886
    Abstract: Provided are compounds of the formula: and pharmaceutically acceptable salts and compositions thereof, which are useful for treating a variety of diseases, disorders or conditions, associated with potassium channels.
    Type: Grant
    Filed: January 23, 2018
    Date of Patent: May 22, 2018
    Assignee: Cadent Therapeutics, Inc.
    Inventors: Dipak Vasantrao Amrutkar, Kelly Foster, Thomas Amos Jacobsen, Martin R. Jefson, Gregg F. Keaney, Janus Schreiber Larsen, Karin Sandager Nielsen
  • Phenyl triazole derivative and its use for modulating the GABAreceptor complex
    Patent number: 9931329
    Abstract: Phenyl triazole derivative (specifically, 1-[6-[[5-(2-fluorophenyl)-3-methyl-triazol-4-yl]methoxy]-3-pyridyl]imidazole-4-carbonitrile or a pharmaceutically acceptable salt thereof), pharmaceutical compositions containing this compound, and methods of treatment therewith. The compound is in particular considered useful for the treatment of central nervous system diseases and disorders which are responsive to modulation of GABAA receptors containing the ?5 subunit.
    Type: Grant
    Filed: November 16, 2015
    Date of Patent: April 3, 2018
    Assignee: SANIONA A/S
    Inventors: Janus Schreiber Larsen, Magnus Gustafsson, Carsten Jessen
  • Phenyl triazole derivative and its use for modulating the GABAreceptor complex
    Patent number: 9884848
    Abstract: This invention relates to a novel phenyl triazole derivative, pharmaceutical compositions containing this compound, and methods of treatment therewith. The compound of the invention is in particular considered useful for the treatment of central nervous system diseases and disorders which are responsive to modulation of GABAA receptors containing the ?5 subunit.
    Type: Grant
    Filed: October 11, 2016
    Date of Patent: February 6, 2018
    Assignee: Saniona A/S
    Inventors: Janus Schreiber Larsen, Magnus Gustafsson, Carsten Jessen
  • POTASSIUM CHANNEL MODULATORS
    Publication number: 20170355708
    Abstract: Provided are novel compounds of Formula (I): and pharmaceutically acceptable salts thereof, which are useful for treating a variety of diseases, disorders or conditions, associated with potassium channels. Also provided are pharmaceutical compositions comprising the novel compounds of Formula (I), pharmaceutically acceptable salts thereof, and methods for their use in treating one or more diseases, disorders or conditions, associated with potassium channels.
    Type: Application
    Filed: June 8, 2017
    Publication date: December 14, 2017
    Inventors: Martin R. Jefson, Gregg F. Keaney, Janus Schreiber Larsen, John A. Lowe, III, John M. McCall
  • PHENYL TRIAZOLE DERIVATIVE AND ITS USE FOR MODULATING THE GABAA RECEPTOR COMPLEX
    Publication number: 20170114045
    Abstract: This invention relates to a novel phenyl triazole derivative, pharmaceutical compositions containing this compound, and methods of treatment therewith. The compound of the invention is in particular considered useful for the treatment of central nervous system diseases and disorders which are responsive to modulation of GABAA receptors containing the ?5 subunit.
    Type: Application
    Filed: October 11, 2016
    Publication date: April 27, 2017
    Inventors: Janus Schreiber Larsen, Magnus Gustafsson, Carsten Jessen
  • Phenyl triazole derivative and its use for modulating the GABAreceptor complex
    Patent number: 9475797
    Abstract: This invention relates to a novel phenyl triazole derivative, pharmaceutical compositions containing this compound, and methods of treatment therewith. The compound of the invention is in particular considered useful for the treatment of central nervous system diseases and disorders which are responsive to modulation of GABAA receptors containing the ?5 subunit.
    Type: Grant
    Filed: June 25, 2013
    Date of Patent: October 25, 2016
    Assignee: Saniona A/S
    Inventors: Janus Schreiber Larsen, Magnus Gustafsson, Carsten Jessen
  • A PHENYL TRIAZOLE DERIVATIVE AND ITS USE FOR MODULATING THE GABAA RECEPTOR COMPLEX
    Publication number: 20160115155
    Abstract: This invention relates to a novel phenyl triazole derivative, pharmaceutical compositions containing this compound, and methods of treatment therewith. The compound of the invention is in particular considered useful for the treatment of central nervous system diseases and disorders which are responsive to modulation of GABAA receptors containing the ?5 subunit.
    Type: Application
    Filed: June 25, 2013
    Publication date: April 28, 2016
    Applicant: SANIONA APS
    Inventors: Janus Schreiber LARSEN, Magnus GUSTAFSSON, Carsten JESSEN
  • PHENYL TRIAZOLE DERIVATIVE AND ITS USE FOR MODULATING THE GABAA RECEPTOR COMPLEX
    Publication number: 20160067234
    Abstract: Phenyl triazole derivative (specifically, 1-[6-[[5-(2-fluorophenyl)-3-methyl-triazol-4-yl]methoxy]-3-pyridyl]imidazole-4-carbonitrile or a pharmaceutically acceptable salt thereof), pharmaceutical compositions containing this compound, and methods of treatment therewith. The compound is in particular considered useful for the treatment of central nervous system diseases and disorders which are responsive to modulation of GABAA receptors containing the ?5 subunit.
    Type: Application
    Filed: November 16, 2015
    Publication date: March 10, 2016
    Applicant: SANIONA APS
    Inventors: Janus Schreiber LARSEN, Magnus GUSTAFSSON, Carsten JESSEN
  • Phenyl triazole derivative and its use for modulating the GABAreceptor complex
    Patent number: 9206160
    Abstract: This invention relates to a novel phenyl triazole derivative, pharmaceutical compositions containing this compound, and methods of treatment therewith. The compound of the invention is in particular considered useful for the treatment of central nervous system diseases and disorders which are responsive to modulation of GABAA receptors containing the ?5 subunit.
    Type: Grant
    Filed: June 25, 2013
    Date of Patent: December 8, 2015
    Assignee: SANIONA APS
    Inventors: Janus Schreiber Larsen, Magnus Gustafsson, Carsten Jessen